Walgreens retreats as CVS quietly takes over suburban pharmacies

Across American suburbs, shuttered Walgreens stores often have handwritten signs indicating prescriptions have moved to a nearby CVS. This pattern is quietly reshaping suburban pharmacy control without either company needing to compete openly. Walgreens is closing roughly 1,200 of its 8,500 U.S. locations through 2027, while CVS is opening new stores and absorbing customers.

Walgreens went private in August 2025 through a $10 billion sale to private equity firm Sycamore Partners, with new CEO Mike Motz replacing Tim Wentworth. Federal and state rules require an orderly transfer of prescription records when a pharmacy closes, often leading to a CVS in nearby markets. CVS has a structural advantage with its ownership of Caremark, a dominant pharmacy benefit manager, giving it an edge in absorbing reimbursement pressure.

CVS posted $106 billion in revenue and a $5.2 billion adjusted operating income in Q2 2026, up more than 35% from the previous year. CVS expects to grow faster than the market as pharmacies close around it. The closure activity is most visible in states like Florida, Texas, Illinois, and California, which have a heavy concentration of Walgreens locations.

Traditional antitrust review is not needed as Walgreens is choosing to stop competing in certain areas. CVS is opening small-format stores, folding in Rite Aid real estate, and expanding its pharmacy business through partnerships with Eli Lilly and Novo Nordisk.